Form 8-K - Current report:
SEC Accession No. 0001641172-25-003135
Filing Date
2025-04-08
Accepted
2025-04-08 08:30:36
Documents
15
Period of Report
2025-04-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44515
2 ex10-1.htm EX-10.1 160757
3 ex99-1.htm EX-99.1 17907
  Complete submission text file 0001641172-25-003135.txt   441819

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE awh-20250402.xsd EX-101.SCH 3012
5 XBRL LABEL FILE awh-20250402_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE awh-20250402_pre.xml EX-101.PRE 24164
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3815
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 25820371
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)